



January 28, 2011

**For Immediate Release**

Company name Otsuka Holdings Co., Ltd.  
 Representative Tatsuo Higuchi  
 President and Representative Director, CEO  
 Code number 4578 First Section , Tokyo Stock Exchange  
 Inquiries Hideki Shirai  
 Director, Investors Relations Department

Otsuka announces 2010 U.S. net sales figures of ABIFILY®

Tokyo Japan – Otsuka Holdings Co., Ltd. (Head office: Chiyoda-ku, Tokyo, Japan; President and Representative Director, CEO: Tatsuo Higuchi, "Otsuka Holdings") announces 2010 U.S. net sales figures of ABILIFY (aripiprazole), the antipsychotic agent marketed worldwide by its wholly owned direct subsidiary Otsuka Pharmaceutical Co., Ltd. (“Otsuka Pharmaceutical”). The results follow Bristol-Myers Squibb Company’s (“Bristol-Myers Squibb”) results announcement for the fourth quarter and full year of 2010 on Thursday, January 27, 2011.

ABILIFY is co-promoted in the U.S. by Otsuka America Pharmaceutical, Inc. (“OAPI,” a wholly owned subsidiary of Otsuka Pharmaceutical) and Bristol-Myers Squibb. Net sales of ABILIFY is reported to OAPI; Otsuka Pharmaceutical pays BMS a fee based on the collaboration agreement. U.S. net sales\*<sup>1</sup> of ABILIFY are reported to OAPI are as follows:

\*<sup>1</sup> Net sales in U.S. and Puerto Rico

OAPI U.S. Net Sales Figure of ABILIFY					
					(\$ in millions)
1 <sup>st</sup> Qtr	2 <sup>nd</sup> Qtr	3 <sup>rd</sup> Qtr	4 <sup>th</sup> Qtr	Year	% change (YTD vs. YTD)
843	880	831	959 *	3,512 *	6.3% *

\* unaudited

About ABILIFY:

Discovered by Otsuka Pharmaceutical Co., Ltd. and jointly developed and commercialized by Otsuka and Bristol-Myers Squibb, ABILIFY is the first and only available dopamine partial agonist and is indicated for the treatment of multiple neurological disorders.

To date, ABILIFY is sold in 65 countries and regions worldwide including Japan with global sales of approximately 370 billion yen in fiscal 2009 accounting for 34.5% of Otsuka Holding’s consolidated results.

About Otsuka Group:

The Otsuka Group is a global organization of 145 healthcare companies with nearly 39,000 employees. Otsuka Holdings Co., Ltd., is the Group’s pure holding company. The main operating companies are Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc., Taiho Pharmaceutical Co., Ltd., Otsuka Warehouse Co., Ltd., and Otsuka Chemical Co., Ltd. The Group operates in 23 countries and regions, conducting diversified businesses in four segments all connected by a focus on health: pharmaceuticals, nutraceuticals, consumer products, and others.